Zimbabwe has declined a significant US healthcare agreement worth 367 million US dollars (£272m) spanning five years due to Washington's demand for sensitive biological samples.
This move came to light after a internal memorandum from December was disclosed, which showed President Emmerson Mnangagwa believed the arrangement was "lopsided".
A government representative later stated that the US was demanding access to biological samples for research and commercial purposes while was unwilling to guarantee the resulting advantages from any future medical innovations.
"We will now turn to the challenging and unfortunate process of scaling back our support in Zimbabwe," said American envoy to Zimbabwe Pamela Tremont in a statement.
The US Embassy said the United States had donated more than $1.9bn in health funding to Zimbabwe over the last twenty years.
A physicians' group in Zimbabwe has called for more talks to find a deal acceptable to all parties so the country's vital HIV programme can proceed.
Broader Background
This development follows a similar case in neighbouring Kenya, where a court halted a related health funding agreement after concerns were raised about the safety of citizens' medical information.
After returning to office recently, US President Donald Trump has drastically cut foreign aid and closed the US Agency for International Development (USAID).
The agency had overseen aid for the American government, but Trump argued its spending was "wasteful" and his government was seeking direct bilateral deals to enhance openness and accountability.
As per reports, Sixteen African countries have to date signed similar health pacts, constituting more than $18.3bn in new funding.
Specifics of the Rejected Agreement
The funds for Zimbabwe would have gone towards "tackling HIV/Aids, TB, malaria, maternal and child health, and preparing for epidemics".
"We believe this collaboration might have yielded extraordinary advantages for Zimbabwean communities, particularly the 1.2 million currently receiving antiretroviral therapy through American-funded programmes," the Ambassador added.
However, government spokesperson Nick Mangwana argued the arrangement was "asymmetrical".
"The proposal required Zimbabwe to share its biological resources and data for a long time, without any corresponding assurance of access to any medical innovations – such as new medicines or tests – that could be developed from that provided information," Mangwana explained.
"Put simply, our country would supply the raw materials for scientific discovery without any assurance that the final treatments would be available to our population if a future disease outbreak arise."
National Interest and International Frameworks
He also said that the US's withdrawal from the World Health Organization (WHO) and its push of one-on-one deals were upending frameworks already established via the international health agency.
The spokesperson gave as an example its Pandemic Benefit-Sharing scheme designed to deal with future global health emergencies.
"This framework is designed to guarantee that when a nation contributes its samples, the resulting advantages – including vaccines and treatments – are distributed fairly, not monopolised exclusively by those with the capability to create them."
These objections over the US deal "are not meant as anti-American sentiment," Mangwana stressed.
"We are open to ongoing discussions with our US partners on how future co-operation could be arranged in a manner that respects the sovereignty and dignity of both nations."
Health Experts Reaction
A leading public health body expressed it understood the government's concerns, but suggested that negotiations must proceed since much of the nation's Aids initiatives relied on external financing.
"Where specific concerns exist, such as those involving information security or agreement terms, these can often be resolved via detailed discussion and mutually agreed protections," the group commented.
This impasse emphasises the complex tensions between accepting crucial foreign assistance and protecting a country's data in an ever more data-driven world.